Products
OAS2 antibody
- Product Name
- OAS2 antibody
- Catalogue No.
- FNab05951
- Size
- 100μg
- Form
- liquid
- Purification
- Immunogen affinity purified
- Purity
- ≥95% as determined by SDS-PAGE
- Clonality
- polyclonal
- Isotype
- IgG
- Storage
- PBS with 0.02% sodium azide and 50% glycerol pH 7.3, -20℃ for 12 months(Avoid repeated freeze / thaw cycles.)
Immunogen
- Immunogen
- 2'-5'-oligoadenylate synthetase 2, 69/71kDa
- UniProt ID
- P29728
- Observed MW
- 66-71kd
Application
- Tested Applications
- ELISA, WB, IHC, IF, IP
- Recommended dilution
- WB: 1:500-1:2000; IP: 1:200-1:1000; IHC: 1:20-1:200; IF: 1:20-1:200
Validated Images
Jurkat cells were subjected to SDS PAGE followed by western blot with FNab05951(OAS2 antibody) at dilution of 1:500
IP Result of anti-OAS2 (IP:FNab05951, 4ug; Detection:FNab05951 1:500) with Jurkat cells lysate 3600ug.
Immunohistochemistry of paraffin-embedded human breast cancer using FNab05951(OAS2 antibody) at dilution of 1:50
- Background
- Interferon-induced, dsRNA-activated antiviral enzyme which plays a critical role in cellular innate antiviral response. In addition, it may also play a role in other cellular processes such as apoptosis, cell growth, differentiation and gene regulation. Synthesizes higher oligomers of 2'-5'-oligoadenylates(2-5A) from ATP which then bind to the inactive monomeric form of ribonuclease L(RNase L) leading to its dimerization and subsequent activation. Activation of RNase L leads to degradation of cellular as well as viral RNA, resulting in the inhibition of protein synthesis, thus terminating viral replication. Can mediate the antiviral effect via the classical RNase L-dependent pathway or an alternative antiviral pathway independent of RNase L.
